The PSTI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PSTI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The PSTI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View PSTI Detailed Price Forecast - CNN Money||View PSTI Detailed Summary - Google Finance|
|View PSTI Detailed Summary - Yahoo! Finance||View PSTI Stock Research & Analysis - Zacks.com|
|View PSTI Trends & Analysis - Trade-Ideas||View PSTI Major Holders - Barrons|
|View PSTI Call Transcripts - NASDAQ||View PSTI Breaking News & Analysis - Seeking Alpha|
|View PSTI Annual Report - CompanySpotlight.com||View PSTI OTC Short Report - OTCShortReport.com|
|View PSTI Fundamentals - TradeKing||View PSTI SEC Filings - Bar Chart|
|View Historical Prices for PSTI - The WSJ||View Performance/Total Return for PSTI - Morningstar|
|View the Analyst Estimates for PSTI - MarketWatch||View the Earnings History for PSTI - CNBC|
|View the PSTI Earnings - StockMarketWatch||View PSTI Buy or Sell Recommendations - MacroAxis|
|View the PSTI Bullish Patterns - American Bulls||View PSTI Short Pain Metrics - ShortPainBot.com|
|View PSTI Stock Mentions - StockTwits||View PSTI Stock Mentions - PennyStockTweets|
|View PSTI Stock Mentions - Twitter||View PSTI Investment Forum News - Investor Hub|
|View PSTI Stock Mentions - Yahoo! Message Board||View PSTI Stock Mentions - Seeking Alpha|
|View Insider Transactions for PSTI - SECform4.com||View Insider Transactions for PSTI - Insider Cow|
|View PSTI Major Holdings Summary - CNBC||View Insider Disclosure for PSTI - OTC Markets|
|View Insider Transactions for PSTI - Yahoo! Finance||View Institutional Holdings for PSTI - NASDAQ|
|View PSTI Stock Insight & Charts - FinViz.com||View PSTI Investment Charts - StockCharts.com|
|View PSTI Stock Overview & Charts - BarChart||View PSTI User Generated Charts - Trading View|
Free Technical Reports on Portola Pharma and Three Additional Biotech Equities
Posted on Thursday July 19, 2018
LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on PTLA sign up now at www.wallstequities.com/registration. WallStEquities.com revisits the Biotech space, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Under evaluation this morning are the following equities: Pluristem Therapeutics Inc. (NASDAQ: PSTI), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Recro Pharma Inc. (NASDAQ: REPH), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN).
Pluristem Signs Collaboration Agreement With Thermo Fisher Scientific
Posted on Monday July 09, 2018
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, announced today that it has entered into a strategic collaboration with Thermo Fisher Scientific to advance fundamental knowledge of cell therapy industrialization and to improve quality control of the end-to-end supply chain. Together, the companies hope to transform cell therapy manufacturing into a large-scale, high capacity industry that will enable the production of millions of therapeutic doses of regenerative medicines.
Pluristem shares jump 2% on news of positive trial of treatment for radiation damage
Posted on Monday June 25, 2018
The Israeli company, which develops placenta-based cell therapies, said a study conducted with Fukushima Medical University of its PLX-R18 cells as a treatment for radiation damage to the gastrointestinal tract and bone marrow found that they significantly increase survival rates, preserve GI stem cells activity that improve the recovery of the system and prevent severe damage to the intestinal lining. The company said the cells may have potential as a multi-organ treatment for acute radiation syndrome, or ARS. "Lethality in ARS originates mainly from radiation-induced injuries to bone marrow and the GI tract, highlighting the importance of the study's purpose and results," Akihiro Inano, Ph.D. of Fukushima University, said in a statement.
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, today reported positive data from studies conducted in collaboration with Fukushima Medical University evaluating PLX-R18 cells as a treatment for radiation damage to the gastrointestinal (GI) tract and bone marrow. Data from these studies showed that PLX-R18 cells significantly increase survival rates, preserve GI stem cells activity that enhance the recovery of the GI system and prevents severe damage to the intestinal lining, suggesting PLX-R18 potential as a multi-organ therapy for acute radiation syndrome (ARS). Under a Memorandum of Understanding (MOU) with Pluristem, Fukushima University, Fukushima Global Medical Science Center, has been developing targeted animal models of ARS and has been testing these models in studies to evaluate the efficacy of PLX-R18 in treating radiation damage to the GI tract and bone marrow of mice.